Drugs / Elironrasib
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05462717 | Sep 2022 → Mar 2027 expected | colorectal carcinoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Revolution Medicines, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07397338 | Jan 2026 → May 2029 expected | colorectal cancer, metastatic neoplasm, non-small cell lung carcinoma | Revolution Medicines, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06162221 | Jan 2024 → Jun 2027 expected | non-small cell lung carcinoma | Revolution Medicines, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06128551 | Nov 2023 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Revolution Medicines, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-08-05 | Revolution Medicines, Inc. | Results Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress revmed.com ↗
Reporting encouraging new combination data in first-line non-small cell lung cancer supporting registrational studies of elironrasib and zoldonrasib |
| 2025-10-22 | Revolution Medicines, Inc. | Results Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor revmed.com ↗
These results will be highlighted in an oral presentation at the AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics in Boston, October 23-25. |
| 2025-07-23 | Revolution Medicines, Inc. | Regulatory Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib revmed.com ↗ |
| 2024-12-02 | Revolution Medicines, Inc. | Results Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio revmed.com ↗
Favorable initial safety profile for combination of pembrolizumab with either RMC-6236 or RMC-6291 supports continued evaluation in non-small cell lung cancer |
| 2024-07-11 | Revolution Medicines, Inc. | Results Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer revmed.com ↗
The data show this activity was further enhanced in the doublet combination with a RAS(ON) G12C-selective inhibitor RMC-4998 (a preclinical tool compound representative of the investigational drug RMC-6291), in preclinical models of KRAS G12C-mutated NSCLC. |
| 2023-10-13 | Revolution Medicines, Inc. | Results Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting revmed.com ↗
First clinical data presentation for RMC-6291, a RASG12C(ON) Inhibitor, highlights encouraging initial tolerability, safety and differentiated anti-tumor activity |
| 2023-08-17 | Revolution Medicines, Inc. | Results Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins revmed.com ↗
Both RMC-4998 and RMC-6291 inactivate oncogenic signaling in KRASG12C-dependent tumor cells and drive deep and durable tumor regressions in human xenograft models of these cancers. |
All press releases naming this drug 8 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elironrasib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06128551 ↗ |
| Known as | RMC-6291 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05462717 ↗ |
| Action | Inhibit | “RMC-6291 (KRAS G12C(ON) inhibitor)” NCT05462717 ↗ |
| Modality | Small molecule | “We designed a natural product-inspired small molecule that remodels the surface of cyclophilin A (CYPA) to create a neomorphic interface with high affinity and selectivity for...” PMID 37590355 ↗ Aug 2023 |
| Route | Oral | “Oral tablet once or twice a day” NCT05462717 ↗ |
| Target | KRAS | “RMC-6291 (KRAS G12C(ON) inhibitor)” NCT05462717 ↗ |